Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 4,721 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Signs and Symptoms, Respiratory Clear all

Conditions: Asthma
Interventions: QAW039 150 mg, QAW039 450 mg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 2,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 46
States / cities: Birmingham, Alabama • Encinitas, California • Newport Beach, California + 41 more

Conditions: Volume Overload, Kidney Failure, Respiratory Failure
Interventions: Share ultrasound measurement of IVC collapsibility to Nephrology Attending, Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypoxia, Extracorporeal Membrane Oxygenation Complication
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Post-acute Sequelae of COVID-19, Depressive Symptoms, Cognitive Dysfunction
Interventions: CI-581a, CI-581b; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Intensive Care Unit Survivors, Informal Caregivers (Family and Friends)
Interventions: coping skills training, education program; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: Chapel Hill, North Carolina • Durham, North Carolina • Pittsburgh, Pennsylvania + 1 more

Conditions: Childhood Cancer, Cancer Survivors
Interventions: POWERbreathe Plus IMT; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 6 Years to 12 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pollution Related Respiratory Disorder, Pollution; Exposure, Dyspnea, Cardiopulmonary
Interventions: Healthy control; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 24 Years to 68 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Interventions: TAK-935, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions: Lenzilumab, Standard of Care; Biological · Drug
Lead sponsor: Humanigen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 18
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more

Conditions: Shy-Drager Syndrome, Orthostatic Hypotension
Interventions: droxidopa; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 20 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
Interventions: Chemoradiation; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 5 more

Conditions: Chronic Obstructive Pulmonary Disease, Aging
Interventions: Fiber Inulin, Placebo Maltodextrin; Dietary Supplement
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, Overweight and Obesity
Interventions: FOCuSEd Integrated Intervention, Enhanced Usual Care; Other
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Boise, Idaho • Chicago, Illinois • Minneapolis, Minnesota + 2 more

Conditions: Critical Illness, COVID-19, PICS, Cognitive Impairment, Mental Health Impairment, Weakness, Muscle, Dysbiosis
Interventions: Fermented Food Diet; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dyspnea
Interventions: Socialization phase, Speech breathing intervention; Behavioral
Lead sponsor: University of Delaware; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Infections, Respiratory, Diarrhea
Interventions: probiotic strain Bb-12, no Bb-12; Other
Lead sponsor: Georgetown University; Other
Eligibility: 2 Years to 4 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Emphysema or COPD, Emphysema, COPD
Interventions: Implantable Artificial Bronchus; Device
Lead sponsor: Pulmair Medical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions: A2B530, xT-Onco with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more

Conditions: Presbylarynx, Aspiration, Spasmodic Dysphonia, Globus Pharyngeus, Larynx Paralysis, Laryngeal Disease, Vocal Cord Paralysis, Iatrogenic Injury, Sensory Neuropathy
Interventions: Cheung-Bearelly Aesthesiometer, Transnasal Laryngoscopy, Questionnaires; Device · Procedure · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Interventions: iNO; Combination Product
Lead sponsor: Bellerophon; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more

Conditions: COPD
Interventions: RESP-FIT, RESP-FIT Comparator; Device · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 40 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: INS018_055, Placebo; Drug
Lead sponsor: InSilico Medicine Hong Kong Limited; Industry
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 8 more

Conditions: Tonsillitis, Post-operative Nausea and Vomiting (PONV), Emergence Delirium, Opioid Analgesic Adverse Reaction, Anesthesia, Pain
Interventions: Dexmedetomidine, Acetaminophen, Ketorolac, Morphine; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 3 Years to 17 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Obstructive Sleep Disordered Breathing
Interventions: tonsillar examination and questionnaire completion; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 5 Years to 28 Years
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

Ultrasound Assessment of Volume in Patients on Continuous Dialysis

The Effect of ECMO on the Pharmacokinetics of the Drugs and Their Clinical Efficacy

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

Improving Psychological Distress Among Critical Illness Survivors and Their Caregivers

Diaphragm Structure and Function in Childhood Cancer Survivors

Lung and Heart Function Across Decades of Life in Health

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

Droxidopa in Treating Patients With Neurogenic Hypotension

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

Fiber Metabolism in Chronic Obstructive Pulmonary Disease

Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention

A Study of Healthy Microbiome, Healthy Mind

Preventing Dyspnea During Speech in Older Speakers

Yogurt Study in Children 2-4 Years Old Attending Daycare

A Multi Center Study Testing a New Implant for Adults With Severe Emphysema

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

RESP-FIT: Technology-Enhanced Self-Management in COPD

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

Opioid Sparing Anesthesia Care for Pediatric Patients Having Tonsil Surgery

Outcomes of Partial Versus Complete Tonsillectomy for Obstructive Sleep Disordered Breathing